<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02162797</url>
  </required_header>
  <id_info>
    <org_study_id>SUPL002</org_study_id>
    <nct_id>NCT02162797</nct_id>
  </id_info>
  <brief_title>Zinc Supplementation Effect on Immune Recovery in HIV Patients</brief_title>
  <official_title>EFFECT OF ZINC SUPPLEMENTATION ON IMMUNE RECOVERY PROGRAM HIV PATIENTS WITH AN IPS MEDELLIN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CES University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IPS Fundación SIAM</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CES University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      INTRODUCTION:

      An adequate zinc supplementation is essential for a good immunological function. However,
      zinc deficiency is seen in more than 50% of adults infected with HIV. The safety and
      efficiency of zinc supplements in the progression of HIV is evaluated in the short-term.

      HYPOTHESIS

      Null hypothesis: Zinc supplementation does not improve the immunological recovery of HIV
      patients after three months of daily consumption.

      Alternate hypothesis: Zinc supplementation improves the immunological recovery of HIV
      patients after three months of daily consumption
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GOAL:

      To assess the effect of zinc supplementation in the natural history of HIV, emphasizing on
      the immunological recovery of patients in a health care provider program in Medellín in 2012.

      METHODS:

      A prospective, randomized, double-blind, controlled clinical trial will be conducted. The
      selected group will consist of male and female patients over 18 years of age, who comply with
      the inclusion criteria, with digital clinical history, in an HIV/AIDS program of a health
      care provider in Medellín. They will receive zinc supplements for 3 months. A comparison will
      be made between the immunological recovery among those patients taking the zinc supplement
      and those who are not. The CD4 lymphocytes value will be taken as an independent variable.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunological Recovery</measure>
    <time_frame>Three months</time_frame>
    <description>Zinc supplementation is expected to enhance the immunological response of HIV+ patients. This can be demonstrated comparing the initial analysis with the final report (3 months later).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EFFECT OF ZINC SUPPLEMENTATION ON IMMUNE RECOVERY PROGRAM HIV PATIENTS</measure>
    <time_frame>THREE MONTHS</time_frame>
    <description>Compare the variation in levels of CD4 lymphocytes at baseline and three months after surgery (zinc or placebo) in each study patient.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>HIV</condition>
  <condition>AIDS</condition>
  <condition>Immunological Deficiency</condition>
  <condition>Inadequate Immune Recovery</condition>
  <condition>Viral Replication</condition>
  <arm_group>
    <arm_group_label>Placebo supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention Group B: Patients who will orally receive a placebo for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>zinc supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention group A. Patients who will orally receive zinc for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Zinc supplementation</intervention_name>
    <description>Intervention group A: Patients who will orally receive zinc for 3 months.</description>
    <arm_group_label>zinc supplementation</arm_group_label>
    <other_name>Zinc Supplementation in Patients With HIV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo supplementation</intervention_name>
    <description>Intervention Group B: Patients who will orally receive a placebo for 3 months.</description>
    <arm_group_label>Placebo supplementation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults suffering from HIV/AIDS, over 18 years of age with first- and second-line
             antiretroviral therapy.

          -  Patients with two viral loads less than 40 copies/ml (viral supression) and a stable
             or inferior CD4 lymphocyte count.

          -  Patients with body mass index over 18.5 kg/m2.

          -  Patients without opportunistic diseases.

        Exclusion Criteria:

          -  Pregnant women.

          -  Hospitalized patients with cognitive disability evaluated by a doctor.

          -  Patients who are unwilling to participate.

          -  Patients taking zinc supplements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heidy Contreras, PhC.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Researcher</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcela Duque, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Researcher</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elsa Vásquez, Biologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Researcher</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MARCELA DUQUE</last_name>
    <phone>3136461538</phone>
    <email>marduque@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>HEIDY CONTRERAS</last_name>
    <phone>3113710971</phone>
    <email>heidycm@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fundación SIAM</name>
      <address>
        <city>Medellín</city>
        <state>Antioquia</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2014</study_first_submitted>
  <study_first_submitted_qc>June 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2014</study_first_posted>
  <last_update_submitted>June 12, 2014</last_update_submitted>
  <last_update_submitted_qc>June 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CES University</investigator_affiliation>
    <investigator_full_name>Heidy Contreras</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>AIDS</keyword>
  <keyword>zinc</keyword>
  <keyword>zinc supplement</keyword>
  <keyword>immunological deficiency</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zinc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

